These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10331825)

  • 1. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis.
    Bosso JA; Bonapace CR; Flume PA; White RL
    Pharmacotherapy; 1999 May; 19(5):620-6. PubMed ID: 10331825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
    Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children.
    Rappaz I; Decosterd LA; Bille J; Pilet M; Bélaz N; Roulet M
    Eur J Pediatr; 2000 Dec; 159(12):919-25. PubMed ID: 11131352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
    Master V; Roberts GW; Coulthard KP; Baghurst PA; Martin A; Roberts ME; Onishko CR; Martin AJ; Linke RJ; Holmes M; Jarvinen A; Kennedy D; Colebatch KA; Hansman D; Parsons DW
    Pediatr Pulmonol; 2001 May; 31(5):367-76. PubMed ID: 11340683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home.
    Vinks AA; Touw DJ; Heijerman HG; Danhof M; de Leede GP; Bakker W
    Ther Drug Monit; 1994 Aug; 16(4):341-8. PubMed ID: 7974622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ceftazidime in dogs following subcutaneous administration and continuous infusion and the association with in vitro susceptibility of Pseudomonas aeruginosa.
    Moore KW; Trepanier LA; Lautzenhiser SJ; Fialkowski JP; Rosin E
    Am J Vet Res; 2000 Oct; 61(10):1204-8. PubMed ID: 11039548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.
    Vinks AA; Brimicombe RW; Heijerman HG; Bakker W
    J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients.
    Byl B; Baran D; Jacobs F; Herschuelz A; Thys JP
    J Antimicrob Chemother; 2001 Aug; 48(2):325-7. PubMed ID: 11481316
    [No Abstract]   [Full Text] [Related]  

  • 11. Susceptibility of pseudomonas aeruginosa to cefepime versus ceftazidime in patients with cystic fibrosis.
    Robinson CA; Kuhn RJ; Craigmyle J; Anstead MI; Kanga JE
    Pharmacotherapy; 2001 Nov; 21(11):1320-4. PubMed ID: 11714203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Echeverría O; Gómez-Lus ML; Prieto J
    J Antimicrob Chemother; 2005 Feb; 55(2):209-13. PubMed ID: 15650000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis.
    Hubert D; Le Roux E; Lavrut T; Wallaert B; Scheid P; Manach D; Grenet D; Sermet-Gaudelus I; Ramel S; Cracowski C; Sardet A; Wizla N; Deneuville E; Garraffo R
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3650-6. PubMed ID: 19528265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
    Smith AL; Fiel SB; Mayer-Hamblett N; Ramsey B; Burns JL
    Chest; 2003 May; 123(5):1495-502. PubMed ID: 12740266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.
    Nicolau DP; Nightingale CH; Banevicius MA; Fu Q; Quintiliani R
    Antimicrob Agents Chemother; 1996 Jan; 40(1):61-4. PubMed ID: 8787880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis.
    Arguedas AG; Stutman HR; Zaleska M; Knupp CA; Marks MI; Nussbaum E
    Am J Dis Child; 1992 Jul; 146(7):797-802. PubMed ID: 1496945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.
    Mouton JW; den Hollander JG
    Antimicrob Agents Chemother; 1994 May; 38(5):931-6. PubMed ID: 8067772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.
    Heilesen AM; Permin H; Koch C; Høiby N
    Scand J Infect Dis; 1983; 15(3):271-6. PubMed ID: 6417770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous infusion of ceftazidime with an elastomeric infusion device.
    Couldry R; Sanborn M; Klutman NE; Strayer AH
    Am J Health Syst Pharm; 1998 Jan; 55(2):145-9. PubMed ID: 9465978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.